Best Overall Response Rate (full analysis population) | Download Table
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
dMMR Recurrent or Advanced Solid Tumors | JEMPERLI (dostarlimab-gxly)
Objective response rate of placebo in randomized controlled trials of anticancer medicines - eClinicalMedicine
Overall Response Rate of 76% in Advanced Melanoma Patients
Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology
Visualization of efficacy endpoints in oncology clinical trials
Objective response rate of placebo in randomized controlled trials of anticancer medicines - ScienceDirect
ORR (Objective Response Rate) and related statistics – Part 1
TECARTUS® Clinical Trial Data for R/R Mantle Cell Lymphoma
Tumor Mutational Burden and Response Rate to PD-1 Inhibition | NEJM
Overall Response Rate | CALQUENCE® (acalabrutinib) 100 mg tablets | For HCPs
Efficacy | Tivdak® (tisotumab vedotin-tftv)
ODOMZO® (sonidegib) | Efficacy Data
Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma | Future Oncology
Response rates Overall response rate and depth of response according to... | Download Scientific Diagram
BRAFTOVI + cetuximab | Overall Response Rate | ORR | BEACON CRC
Overall response rate | Download Table
Best overall response rate and clinical benefit rate for patients with... | Download Scientific Diagram
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire
Overall response rate | Download Table
Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates | JCO Clinical Cancer Informatics
Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma | Semantic Scholar
Durable Response Rate
Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual
Efficacy I PLUVICTO
Efficacy | BALVERSA® (erdafitinib) HCP
Cell therapy doubles survival, response rates in advanced melanoma
